clindamycin | Dalacin vaginal suppositories 100 mg, 3 pcs.
Special Price
$27.16
Regular Price
$36.00
In stock
SKU
BID462855
Latin name
Dalacin
Dalacin
Latin name
Dalacin
Packing
3 pcs
Indications
Bacterial vaginosis.
Contraindications
Hypersensitivity to clindamycin, lincomycin or any component of the drug Dalacin.
Use during pregnancy and lactation
Adequate and well-controlled studies on the use of the drug in the first trimester of pregnancy have not been conducted. The use of Dalacin in the first trimester of pregnancy is possible only if the intended benefit outweighs the potential risk to the fetus.
When using clindamycin preparations in the II and III trimesters of pregnancy in dosage forms for intravaginal administration, there was no increase in the frequency of congenital malformations of the fetus. If Dalacin is used in the II and III trimesters of pregnancy (although there have been no official studies on the use of suppositories during pregnancy), an unfavorable effect on the fetus is unlikely.
There are currently no data on the excretion of clindamycin with breast milk with intravaginal administration of dalacin. However, it was found that when clindamycin is administered orally or parenterally, a certain amount is found in breast milk. Therefore, when deciding on the possibility of prescribing Dalacin during lactation (breastfeeding), the expected benefit for the mother and the possible risk for the child should be compared.
Composition
1 suppository contains clindamycin (in the form of phosphate) 100 mg
excipients: solid fat (Witepsol H-32, a mixture of triglycerides, diglycerides and monoglycerides).
Dosage and administration
A single dose (1 suppository) is administered into the vagina at bedtime for 3 consecutive days.
Suppositories can be administered without an applicator and with an applicator. After each use, the applicator should be washed with warm water and soap and dried well.
Side effects
The incidence of the following side effects is less than 10%.
From the reproductive system: irritation of the mucous membrane of the vulva and vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual irregularities, uterine bleeding, abnormal births, endometriosis.
From the urinary system: dysuria, urinary tract infections (including pyelonephritis), proteinuria.
From the digestive system: generalized abdominal pain, localized abdominal pain, abdominal cramps, bloating, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, halitosis, taste perversion.
From the side of the central nervous system: dizziness, headache.
Dermatological reactions: rash, pruritus, maculopapular rash, erythema, skin candidiasis.
Allergic reactions: urticaria.
From the endocrine system: glucosuria, hyperthyroidism.
On the part of the body as a whole: fungal infections, fever, side pain, back pain, lower abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nosebleeds, deviation of the results of microbiological analyzes from normal.
Local reactions: itching and pain at the injection site.
Drug Interaction
In vitro, an antagonistic interaction between clindamycin and erythromycin has been demonstrated.
Clindamycin has been found to interfere with neuromuscular transmission during systemic use, therefore, enhancement of peripheral muscle relaxant action is possible. This fact should be taken into account when appointing the latter with Dalacin.
No interactions were observed in pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms.
Storage conditions
The product should be stored out of the reach of children at a temperature not exceeding 25 РC. Do not freeze.
Shelf life
3 years.
Deystvuyushtee substance
Clindamycin
dosage form
vaginal suppositories
Prescribing
Prescribing
Adults, For women
Dalacin
Packing
3 pcs
Indications
Bacterial vaginosis.
Contraindications
Hypersensitivity to clindamycin, lincomycin or any component of the drug Dalacin.
Use during pregnancy and lactation
Adequate and well-controlled studies on the use of the drug in the first trimester of pregnancy have not been conducted. The use of Dalacin in the first trimester of pregnancy is possible only if the intended benefit outweighs the potential risk to the fetus.
When using clindamycin preparations in the II and III trimesters of pregnancy in dosage forms for intravaginal administration, there was no increase in the frequency of congenital malformations of the fetus. If Dalacin is used in the II and III trimesters of pregnancy (although there have been no official studies on the use of suppositories during pregnancy), an unfavorable effect on the fetus is unlikely.
There are currently no data on the excretion of clindamycin with breast milk with intravaginal administration of dalacin. However, it was found that when clindamycin is administered orally or parenterally, a certain amount is found in breast milk. Therefore, when deciding on the possibility of prescribing Dalacin during lactation (breastfeeding), the expected benefit for the mother and the possible risk for the child should be compared.
Composition
1 suppository contains clindamycin (in the form of phosphate) 100 mg
excipients: solid fat (Witepsol H-32, a mixture of triglycerides, diglycerides and monoglycerides).
Dosage and administration
A single dose (1 suppository) is administered into the vagina at bedtime for 3 consecutive days.
Suppositories can be administered without an applicator and with an applicator. After each use, the applicator should be washed with warm water and soap and dried well.
Side effects
The incidence of the following side effects is less than 10%.
From the reproductive system: irritation of the mucous membrane of the vulva and vagina, vaginal pain, vaginal discharge, vaginal candidiasis, vulvovaginitis, trichomonas vaginitis, vaginal infections, menstrual irregularities, uterine bleeding, abnormal births, endometriosis.
From the urinary system: dysuria, urinary tract infections (including pyelonephritis), proteinuria.
From the digestive system: generalized abdominal pain, localized abdominal pain, abdominal cramps, bloating, dyspepsia, nausea, vomiting, diarrhea, constipation, flatulence, halitosis, taste perversion.
From the side of the central nervous system: dizziness, headache.
Dermatological reactions: rash, pruritus, maculopapular rash, erythema, skin candidiasis.
Allergic reactions: urticaria.
From the endocrine system: glucosuria, hyperthyroidism.
On the part of the body as a whole: fungal infections, fever, side pain, back pain, lower abdominal pain, generalized pain, bacterial infections, inflammatory edema, upper respiratory tract infections, nosebleeds, deviation of the results of microbiological analyzes from normal.
Local reactions: itching and pain at the injection site.
Drug Interaction
In vitro, an antagonistic interaction between clindamycin and erythromycin has been demonstrated.
Clindamycin has been found to interfere with neuromuscular transmission during systemic use, therefore, enhancement of peripheral muscle relaxant action is possible. This fact should be taken into account when appointing the latter with Dalacin.
No interactions were observed in pharmacodynamic, pharmacokinetic or clinical studies of these dosage forms.
Storage conditions
The product should be stored out of the reach of children at a temperature not exceeding 25 РC. Do not freeze.
Shelf life
3 years.
Deystvuyushtee substance
Clindamycin
dosage form
vaginal suppositories
Prescribing
Prescribing
Adults, For women
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review